What are the diagnostic criteria for diabetes and the recommended initial management, including lifestyle modification and first‑line pharmacotherapy?

Diagnosis and Management of Diabetes Mellitus

Diagnostic Criteria

Diabetes is diagnosed when any one of the following criteria is met on two separate occasions (or once if symptomatic with confirmatory findings):

• Fasting plasma glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) after an 8-hour fast 1, 2
• 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test (OGTT) 1, 3, 2
• Random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) 1, 2
• HbA1c ≥ 6.5% using a standardized assay 1, 4

Prediabetes Categories

• Impaired fasting glucose (IFG): FPG 100–125 mg/dL (5.6–6.9 mmol/L) 5
• Impaired glucose tolerance (IGT): 2-hour OGTT glucose 140–199 mg/dL (7.8–11.0 mmol/L) 5, 3
• Elevated HbA1c: 5.7–6.4% indicates increased diabetes risk 4

Important diagnostic nuances: A single "diabetic-type" glucose measurement is sufficient for diagnosis if the patient has classic symptoms of hyperglycemia, HbA1c ≥ 6.5%, or unequivocal diabetic retinopathy 3. However, HbA1c below 6.5% does not exclude diabetes; OGTT may detect cases missed by FPG alone, particularly in high-risk populations 4.

---

Initial Management Strategy

Lifestyle Modifications (Foundation for All Patients)

Weight loss and physical activity are the cornerstones of initial therapy:

• Target 5–7% body weight reduction through caloric restriction in overweight/obese patients 5, 6
• Prescribe ≥ 150 minutes per week of moderate-intensity aerobic activity (e.g., brisk walking) plus resistance training on ≥ 2 non-consecutive days per week 1, 6
• Interrupt prolonged sedentary periods (> 30 minutes) with brief standing or walking 1
• Adopt a heart-healthy dietary pattern emphasizing vegetables, whole grains, lean protein, and limiting saturated fat and sodium to < 2 g/day 6

---

First-Line Pharmacotherapy

Metformin is the preferred initial pharmacologic agent and should be started at diagnosis alongside lifestyle modifications unless contraindicated 1, 6.

Metformin Initiation Protocol

• Starting dose: 500 mg once or twice daily with meals to minimize gastrointestinal side effects 1, 7
• Titration: Increase by 500 mg weekly to a target of 2000 mg daily (1000 mg twice daily), which provides maximal glucose-lowering efficacy 1, 7
• Extended-release formulation can be given once daily for improved tolerability 1
• Continue metformin indefinitely as foundational therapy even when other agents are added, unless contraindicated 1, 7

Metformin Benefits Beyond Glucose Lowering

• Reduces cardiovascular events and mortality 1, 6
• Weight-neutral or promotes modest weight loss 1
• Minimal hypoglycemia risk when used alone 1, 7
• Low cost and extensive safety record 1

Renal Function Considerations

• Safe to initiate and continue when eGFR ≥ 30 mL/min/1.73 m² 1, 7
• Reduce dose by 50% when eGFR 45–59 mL/min/1.73 m² 7
• Limit to 1000 mg daily when eGFR 30–44 mL/min/1.73 m² 7
• Discontinue when eGFR < 30 mL/min/1.73 m² 1, 7

Monitoring for Vitamin B12 Deficiency

• Check vitamin B12 periodically (every 6–12 months) in patients on long-term metformin, especially if anemia or peripheral neuropathy develops 1, 7

---

When to Add a Second Agent

If HbA1c remains > 7% after 3 months of optimized metformin plus lifestyle modifications, add a second agent immediately—do not delay 1, 6.

Selection of Second Agent Based on Comorbidities

Patients with Established ASCVD or High Cardiovascular Risk

Add a GLP-1 receptor agonist (e.g., semaglutide, liraglutide, dulaglutide) to metformin 1, 6:

• Provides 0.6–0.8% additional HbA1c reduction (semaglutide up to 1.5%) 1, 7
• Reduces major adverse cardiovascular events by 26–29% 7, 6
• Liraglutide demonstrated 22% reduction in cardiovascular death 6
• Promotes 2–5 kg weight loss 1, 7
• Minimal hypoglycemia risk when not combined with sulfonylureas or insulin 1, 7
• Preferred over insulin when possible for patients with ASCVD 1

Patients with Heart Failure or Chronic Kidney Disease

Add an SGLT2 inhibitor (e.g., empagliflozin, dapagliflozin, canagliflozin) to metformin 1, 6:

• Reduces CKD progression by 24–39% 6
• Lowers heart failure hospitalizations and cardiovascular mortality independent of glucose lowering 1, 6
• Empagliflozin reduced cardiovascular death by 38% 6
• Provides 0.5–0.8% HbA1c reduction and promotes weight loss 7
• No hypoglycemia risk when used with metformin alone 7
• Initiate when eGFR ≥ 30 mL/min/1.73 m²; continue for cardio-renal protection even if eGFR declines below initiation threshold 6

Patients with Both ASCVD and HF/CKD

Use triple therapy: metformin + SGLT2 inhibitor + GLP-1 receptor agonist 6:

• Maximizes cardio-renal protection through complementary mechanisms 1, 6
• Prioritize SGLT2 inhibitor when HF or CKD dominates; prioritize GLP-1 agonist when ASCVD or weight loss is primary goal 6

Alternative Second Agents (When GLP-1 RA or SGLT2i Contraindicated)

• DPP-4 inhibitors (sitagliptin, linagliptin): Modest HbA1c reduction (0.5–0.8%), weight-neutral, no hypoglycemia risk, but lack proven cardiovascular benefit 1, 6
• Thiazolidinediones (pioglitazone): Effective glucose lowering but risk of weight gain and fluid retention; use selectively 6
• Sulfonylureas: Avoid in older adults due to markedly increased hypoglycemia risk (7-fold higher than metformin) and 2-fold higher all-cause mortality 7

---

When to Initiate Insulin

Start basal insulin immediately in the following scenarios 1, 8:

• HbA1c ≥ 10% (86 mmol/mol) 1, 7
• Fasting glucose ≥ 300 mg/dL (16.7 mmol/L) 1, 8
• Symptomatic hyperglycemia (polyuria, polydipsia, weight loss) or evidence of catabolism 1
• Presence of ketosis or ketoacidosis 7

Basal Insulin Initiation Protocol

• Starting dose: 10 units once daily at bedtime or 0.1–0.2 units/kg body weight 1, 8
• For severe hyperglycemia (HbA1c ≥ 10%), use the higher end (0.2 units/kg) 7
• Titrate by 2–4 units every 3 days until fasting glucose reaches 80–130 mg/dL without hypoglycemia 1, 8
• Continue metformin when adding insulin to reduce insulin requirements, mitigate weight gain, and preserve cardiovascular benefit 1, 7

When to Add Prandial Insulin

• If HbA1c remains > 7% after 3–6 months despite optimized basal insulin, add rapid-acting prandial insulin before the largest meal 1, 7
• Starting dose: 4 units or 10% of basal dose 1, 7
• Titrate by 1–2 units every 3 days based on 2-hour postprandial glucose 1

---

Glycemic Targets

For most non-pregnant adults with diabetes, target HbA1c < 7% to reduce microvascular and macrovascular complications 1, 7, 6.

More Stringent Target (HbA1c < 6.5%)

• Consider for younger patients with short disease duration, long life expectancy, no significant CVD, and when achievable without hypoglycemia or treatment burden 7, 6

Less Stringent Target (HbA1c 7.5–8.0%)

• Appropriate for older adults (≥ 65 years), limited life expectancy (< 10 years), history of severe hypoglycemia, advanced complications, or extensive comorbidities 1, 7, 6

---

Monitoring and Follow-Up

• Measure HbA1c every 3 months until target is reached, then continue quarterly 1, 7, 6
• Check fasting glucose daily during insulin titration 8
• Assess renal function (eGFR) at baseline and annually to guide metformin and SGLT2 inhibitor dosing 7, 6
• Screen for vitamin B12 deficiency in patients on long-term metformin 1, 7
• Reevaluate medication regimen every 3–6 months and adjust based on efficacy, hypoglycemia risk, weight effects, side effects, cost, and patient preferences 1

---

Critical Pitfalls to Avoid

• Do not delay insulin initiation when HbA1c ≥ 10% or glucose ≥ 300 mg/dL; oral agents alone are insufficient 1, 7
• Do not discontinue metformin when adding insulin or other agents unless contraindicated; it remains foundational therapy 1, 7
• Avoid therapeutic inertia: Intensify therapy within 3 months if HbA1c remains above target, as delays increase complication risk 1, 6
• Do not combine GLP-1 receptor agonists with DPP-4 inhibitors; no additional benefit is demonstrated 1, 7
• Do not add sulfonylureas to insulin regimens; this markedly raises hypoglycemia risk without cardiovascular benefit 7
• Do not use sulfonylureas in older adults due to severe hypoglycemia risk and increased mortality 7

---

Early Combination Therapy

For patients with HbA1c ≥ 9% at diagnosis, consider immediate dual therapy (metformin + basal insulin or metformin + GLP-1 RA) to achieve rapid glycemic control and prevent metabolic decompensation 1, 7.